ClinicalTrials.gg
CompletedNCT04348175Updated Jun 30, 2021

A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment

A Phase 1 interventional study of Setmelanotide in Renal Insufficiency, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 83 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-30.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 83 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
216th of 468
32 · median 32
Started
2020
with 18 others
Phase 1
232 of 553
14 open now
Registered
417th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 216th largest by enrollment of the 468 interventional ones that give a count, is one of 19 that started in 2020, is one of 232 in phase 1, and was the 417th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 83 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, multi-center, open-label, single-dose study designed to assess the effect of renal impairment on the PK of setmelanotide. A total of approximately 32 subjects (approximately 8 subjects in each renal impairment group and 8 healthy subjects with normal renal function) are planned to be enrolled across 4 centers in the United States. At screening, subjects will be assigned to a study group according to eGFR.

Cohort A - Mild Renal Impairment

Cohort B - Moderate Renal Impairment

Cohort C - Severe Renal Impairment

Cohort D - Normal Renal Function (control)

03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 83 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is male or female 18 to 83 years of age, inclusive.
  2. The subject has a of 22 to 40 kg/m2, inclusive, at screening.
  3. Female subjects of must use an acceptable method of (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) or be surgically sterile (ie, hysterectomy, bilateral tubal ligation or bilateral oophorectomy), or (defined as amenorrhea 12 consecutive months and documented plasma follicle-stimulating hormone level in the postmenopausal range according to the laboratory used). Female subjects must have a negative pregnancy test at screening and before the first dose of study drug and must not be lactating.

    Male subjects with female partners of childbearing potential must be vasectomized, be willing to use an acceptable method of birth control, or practice abstinence during the study. Male subjects must not donate sperm during and for 90 days following their participation in the study.

  4. The subject agrees to comply with all protocol requirements.
  5. The subject is able to provide written .

    Additional Inclusion Criteria for Subjects with Renal Impairment Only (Cohorts A, B, and C):

  6. The subject has mild, moderate, or severe renal impairment as determined by and calculated using the MDRD formula.
  7. The subject's renal insufficiency or other related concomitant medical conditions (eg, hypertension, diabetes, anemia) have remained stable for at least 3 months before study drug dosing.
  8. The subject has a resting blood pressure of 90 to 165 mm Hg (systolic) and 45 to 100 mm Hg (diastolic). Measurement can be repeated if the subject has an elevated value that is not consistent with previous history.
  9. The subject has a of \<500 msec.
  10. The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12-lead results, and physical examination findings, except for findings that, as judged by the investigator, are consistent with the subject's renal impairment or other stable concomitant medical conditions.

    Additional Inclusion Criteria for Healthy Subjects Only (Cohort D):

  11. The subject has normal renal function (≥90 mL/min) as determined by eGFR calculated using the MDRD formula.
  12. The subject will be "matched" to previous Cohorts A, B, and C with regards to age, sex, and BMI characteristics. Each subject in Cohort D will be within 20% of the median age and BMI of the combined median age and BMI across Cohorts A, B, and C.
  13. The subject has a resting blood pressure of 90 to 150 mm Hg (systolic) and 40 to 100 mm Hg (diastolic).
  14. The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12-lead ECG results, and physical examination findings.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a history or clinical manifestations of a significant neurological, cardiovascular, gastrointestinal, pulmonary, hematologic, immunologic, hepatic, genitourinary, endocrine, metabolic, or psychiatric disease that would preclude study participation, as judged by the investigator.
  2. The subject has a positive test result for Types 1 or 2 antibodies or surface antigen at screening.
  3. The subject has a history of alcoholism or drug abuse within 3 months before screening.
  4. The subject is unable or unwilling to abstain from alcohol, marijuana and related substances, caffeine, cigarette smoking, vaping, or any form of tobacco or nicotine from 48 hours prior to study drug dosing until completing study assessments on Day 5.
  5. The subject is involved in strenuous activity or contact sports within 24 hours of the first dose of study drug or during the study.
  6. The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  7. The subject has a history of relevant drug and/or food allergies (ie, allergy to setmelanotide or any , or any significant food allergy).
  8. The subject has used prescription drugs from 1 week prior to randomization and throughout the study, except for prescription medications used for the treatment of stable concomitant conditions; examples include the following: diabetes, hypertension, hypercholesterolemia, hyperlipidemia or hypothyroidism. Medications used to treat these indications are allowed, so long as the subject has been on a stable dose for at least 2 weeks prior to randomization and plans to continue a stable dose throughout the study.
  9. The subject has received study drug in another study within 30 days of dosing.
  10. The subject has a positive test result for drugs of abuse (including marijuana, and except positive test results associated with prescription medications that have been reviewed and approved by the investigator) or alcohol at screening or before the first dose of study drug.
  11. The subject has or AST >2 × at screening.
  12. The subject has >10%. With Sponsor approval, a subject who has a HbA1c >10% may be enrolled into the study if, in the opinion of the primary investigator, the subject's diabetes is reasonably controlled and the subject is otherwise appropriate for this study.
  13. The subject has any personal history of cancer (unless stable and in remission for ≥5 years), multiple atypical nevi, nevoid basal cell carcinoma syndrome, or nonmelanoma skin cancer requiring treatment beyond local excision.
  14. The subject has any close family history (parents or siblings) of melanoma.
  15. The subject has significant dermatologic findings relating to melanoma or premelanoma skin lesions, determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist, the principle investigator, or a nurse practitioner (ordered by preference) . Any concerning lesions identified during screening will be biopsied and results known to be benign prior to enrollment. If the pretreatment results are of concern, the subject may need to be excluded from the study.
  16. The subject has history of recent surgery (within 60 days of screening).
  17. The subject has current or recent (within last month) infection or viral illness.
  18. In the opinion of the investigator, the subject is not suitable for entry into the study.

    Additional Exclusion Criteria for Subjects with Renal Impairment Only (Cohorts A, B, and C):

  19. The subject has a positive test result for antibodies to virus with evidence of viral load at screening.
  20. The subject has nephrotic syndrome, defined as urine dipstick 4+ for protein and plasma albumin \<3.0 g/dL, and then confirmed if proteinuria >5 g/day.
  21. The subject has renal impairment due to rapidly growing, space-occupying lesions (eg, carcinoma of the kidney, tuberculosis).
  22. Subject has a history of renal transplant.
  23. The subject has a value less than 8.0 g/dL.
  24. The subject has a clinically relevant immunologic disease.

    Additional Exclusion Criteria for Healthy Subjects Only (Cohort D):

  25. The subject has a positive test result for antibodies to hepatitis C virus at screening.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Mild impairment

    Drug: Setmelanotide

  • Experimental
    Moderate impairment

    Drug: Setmelanotide

  • Experimental
    Severe impairment

    Drug: Setmelanotide

  • Experimental
    Normal (control)

    Drug: Setmelanotide

Interventions

  • Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter - Peak Plasma Concentration (Cmax)

    The primary objective of this study is to evaluate the PK of a single dose of Setmelanotide administered SC in subjects with varying degrees of renal impairment and that of healthy matched control subjects.

    Time frame: 5 days

  2. Pharmacokinetic Parameter - Area under the plasma concentration versus time curve (AUC)

    The primary objective of this study is to evaluate the PK of a single dose of Setmelanotide administered SC in subjects with varying degrees of renal impairment and that of healthy matched control subjects.

    Time frame: 5 days

Secondary outcomes

  1. Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    The secondary objective of this study is to evaluate the safety and tolerability of a single dose of Setmelanotide administered SC in subjects with varying degrees of renal impairment.

    Time frame: 5 days

  2. Number of Participants with Abnormal Vital Sign Findings

    Vital signs will include systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.

    Time frame: 5 days

  3. Number of subjects with Abnormal Electrocardiogram (ECG) findings

    Electrocardiogram assessments will include comments on whether the tracings are normal or abnormal, rhythm, presence of arrhythmia or conduction defects, wave morphology, any evidence of myocardial infarction, or ST-segment, T-Wave, and U Wave abnormalities.

    Time frame: 5 days

  4. Number of subjects with Abnormal Findings in Physical Examination

    A full physical examination will include, at minimum, assessment of skin, head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular, abdomen, lymph nodes, and musculoskeletal system/extremities.

    Time frame: 5 days

07

Study locations

4 sites
  • University of Miami
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
  • Marshfield Clinic Research Institute
    Marshfield, Wisconsin 54449, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Apr 2021, 9 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Apr 16, 2020
StartActual
Jul 9, 2020
Primary completionActual
Apr 17, 2021
CompletionActual
Apr 17, 2021
Last update
Jun 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04348175
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
Jul 9, 2020
Primary completion
Apr 17, 2021
Completion
Apr 17, 2021
Last update
Jun 30, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion